Dr. Mason on the Impact of the PROTECT Study on Treatment Decisions for Prostate Cancer

Malcolm Mason, MD
Published: Tuesday, Jan 23, 2018



Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, on how the results from the PROTECT study impact a clinician's decision when treating patients with prostate cancer.

In the study, a total of 1643 men were randomized to surgery, radiotherapy, and active monitoring with no meaningful differences among the 3 groups at baseline. The primary endpoint of prostate cancer-specific mortality was approximately 1% in each group.

The data from this study suggest that patients with low-risk disease should be offered active surveillance in preference to immediate treatment. However according to Mason, it is not wrong to treat them, but the patients should be adequately informed about the data and the consequences. There is a trade-off to be had between the side effects of immediate surgery or radiotherapy versus the increased likelihood of disease progression if they have deferred treatment.

The effectiveness of anticancer treatments as curative treatments appear to be equivalent—neither is free of side effects, but the safety profiles are different. This is where a discussion is needed between the physician and the patient to decide what is best.
 


Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, on how the results from the PROTECT study impact a clinician's decision when treating patients with prostate cancer.

In the study, a total of 1643 men were randomized to surgery, radiotherapy, and active monitoring with no meaningful differences among the 3 groups at baseline. The primary endpoint of prostate cancer-specific mortality was approximately 1% in each group.

The data from this study suggest that patients with low-risk disease should be offered active surveillance in preference to immediate treatment. However according to Mason, it is not wrong to treat them, but the patients should be adequately informed about the data and the consequences. There is a trade-off to be had between the side effects of immediate surgery or radiotherapy versus the increased likelihood of disease progression if they have deferred treatment.

The effectiveness of anticancer treatments as curative treatments appear to be equivalent—neither is free of side effects, but the safety profiles are different. This is where a discussion is needed between the physician and the patient to decide what is best.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x